Literature DB >> 33241254

Controversies in Sepsis Management-What is the Way Forward?

Alvin Hy Lo1, Adrian Cl Kee, Andrew Li, Francesca Rubulotta.   

Abstract

Sepsis is life-threatening and might potentially progress from dysregulation to severe organ dysfunction. It is recognised by the World Health Organisation as a global health priority. The mortality rate for sepsis has decreased in many countries, and this is credited to the earlier recognition and treatment of this complex syndrome. In 2002, the Surviving Sepsis Campaign was launched, and there have been several revisions to the sepsis recommendations therefrom. The latest sepsis guidelines focus on viral as well as bacterial infections, and advise that initiating resuscitation and management should take place within one hour from when sepsis is initially suspected. Numerous studies and guidelines pertaining to sepsis management have been published over the past 2 decades. The use of novel therapies and alternative adjunctive therapies has tremendous potential in sepsis management. Debates amongst intensivists exist with the creation of updated sepsis guidelines and advances in treatment. The present review article provides both a summary and recommendations based on the latest clinical evidence and controversies around sepsis management.

Entities:  

Mesh:

Year:  2020        PMID: 33241254

Source DB:  PubMed          Journal:  Ann Acad Med Singap        ISSN: 0304-4602            Impact factor:   2.473


  2 in total

1.  Early fluid bolus in adults with sepsis in the emergency department: a systematic review, meta-analysis and narrative synthesis.

Authors:  Gladis Kabil; Steven A Frost; Deborah Hatcher; Amith Shetty; Jann Foster; Stephen McNally
Journal:  BMC Emerg Med       Date:  2022-01-11

2.  Effect of procalcitonin on the severity and prognostic value of elderly patients with a severe infection of oral and maxillofacial space.

Authors:  Xin-Yan Lin; Yu-Zhao Lin; Shao-Hua Lin; Jun-Jie Lian
Journal:  Medicine (Baltimore)       Date:  2022-08-26       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.